Yannis Hamidou | Immunotherapy |

Published on by Top Pharmaceutical

Mr. Yannis Hamidou | Immunotherapy | Best Researcher Award

Yannis Hamidou at Amiens Picardie University Hospital | France

Mr. Yannis Hamidou is a dedicated rheumatologist currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, France. With a strong academic background in medical sciences, rheumatology, and sports medicine, he has actively contributed to clinical research focusing on autoimmune and inflammatory diseases. His expertise spans therapeutic innovations, patient-centered care, and multidisciplinary collaborations aimed at improving outcomes in rheumatology and intensive care settings. Through his clinical practice and research endeavors, Mr. Hamidou has developed a reputation for excellence in precision treatment strategies and evidence-based medicine, significantly impacting rheumatology healthcare and contributing to advancements in patient management practices.

Publication Profile 

Orcid

Education 

Mr. Yannis Hamidou completed his postgraduate diploma in medical sciences, laying the foundation for his medical career. He successfully defended his medical thesis , advancing his academic and clinical expertise. To specialize further, he obtained a postgraduate diploma in rheumatology, focusing on autoimmune and inflammatory disorders. Additionally, he completed a specialization in sports medicine and earned the BPC certification, broadening his clinical competencies. This comprehensive academic training has equipped him with extensive knowledge across internal medicine, rheumatology, and sports-related healthcare, preparing him for leadership roles in clinical care, research, and education.

Experience 

Mr. Yannis Hamidou is currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, where he integrates clinical care with research responsibilities. His work in intensive care medicine includes serving as Principal Investigator for an observational clinical study, focusing on chronic inflammatory diseases in critical care settings. Alongside his clinical duties, he actively participates in developing patient-specific treatment strategies for autoimmune and rheumatologic disorders. His multidisciplinary experience spans rheumatology, sports medicine, and internal medicine, providing comprehensive care solutions. He also contributes to academic teaching and mentoring, fostering evidence-based clinical practices while engaging in ongoing research aimed at improving patient outcomes.

Awards and Honors 

Mr. Yannis Hamidou academic achievements and clinical leadership reflect his professional excellence. His appointments, including Clinic Chief Assistant at CHU Amiens-Picardie and Principal Investigator roles in clinical studies, highlight his recognition within the medical community. His selection for advanced training in rheumatology, sports medicine, and critical care research further emphasizes his commitment to advancing medical science. Future recognitions are anticipated as his contributions to rheumatology research, patient care innovations, and academic scholarship continue to grow, positioning him as a promising leader in the field of rheumatology and clinical medicine in France.

Research Focus 

Mr. Yannis Hamidou research primarily targets autoimmune and inflammatory disorders, with a focus on therapeutic innovations and patient outcome optimization. His work in rheumatology explores the long-term maintenance of advanced therapies like Janus kinase inhibitors and investigates biomarkers such as fecal calprotectin for early disease detection. Additionally, he has contributed to understanding mortality causes in intensive care settings among patients with chronic inflammatory diseases. By integrating real-world data and observational clinical research, his studies aim to refine diagnostic precision, enhance treatment strategies, and inform evidence-based clinical guidelines, ultimately improving healthcare delivery for patients with complex rheumatologic conditions.

Publication Top Notes

Jl Clua-Espuny | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Assist Prof. Dr. Jl Clua-Espuny | Personalized Medicine | Best Researcher Award

Ebrictus Group at IDIAP Jordi Gol | Spain

Assist. Prof. Dr. JL Clua-Espuny is a distinguished academic and healthcare professional with extensive experience in medicine, primary healthcare, and medical education. He has served in various leadership and academic roles across prestigious institutions, including Universitat Rovira i Virgili, Universidad Miguel Hernández de Elche, and the Institut Català de la Salut. His expertise spans family medicine, health policy, and clinical research, with a strong commitment to improving patient care and medical training. Throughout his career, he has mentored numerous doctoral candidates, contributed to healthcare policy initiatives, and advanced research in cardiovascular diseases, primary care innovation, and public health strategies.

Publication Profile 

Orcid

Education 

Assist. Prof. Dr. JL Clua-Espuny holds multiple advanced degrees, including a Doctorate in Medicine and a Master’s in Primary Care from Universidad Miguel Hernández de Elche. He also completed specialized master’s programs in Health Economics and Healthcare Management from the University of Barcelona and advanced training in Quality Management at Universidad Autonoma de Barcelona and Fundació Avedis Donabedian. Additionally, he earned postgraduate diplomas in Primary Care Management and Quality Evaluation Methodologies and holds dual degrees in Medicine and Philosophy/Psychology from the University of Barcelona. His academic path reflects a dedication to integrating medical, administrative, and research excellence to improve healthcare delivery systems.

Experience 

Assist. Prof. Dr. JL Clua-Espuny career spans healthcare, academia, and research. He served as Director of Primary Care at the Institut Català de la Salut, Vice-President of the Health Council in Tortosa, and Coordinator of Health Plans for the Catalan Health Service. In academia, he has been a professor and tutor at Universitat Rovira i Virgili and Universidad Miguel Hernández de Elche, guiding numerous doctoral and master’s theses. His research affiliations include the Institut Recerca IDIAP Jordi Gol. He has combined clinical practice, academic instruction, healthcare leadership, and policy planning, contributing significantly to primary care innovations and medical education reforms in Spain.

Awards and Honors 

Assist. Prof. Dr. JL Clua-Espuny has received multiple honors for his contributions to medicine, education, and research. He earned the Premio Extraordinario de Doctorado for academic excellence and has been recognized for advancing primary healthcare research and education in Catalonia. His leadership roles in healthcare institutions and medical associations highlight his influence in shaping health policy and service delivery. He has been invited to collaborate in national and regional healthcare planning, reflecting his reputation as an expert in primary care management and cardiovascular health research. His mentorship of numerous doctoral theses further illustrates his commitment to academic excellence and professional development.

Research Focus 

Assist. Prof. Dr. JL Clua-Espuny research centers on primary healthcare, cardiovascular disease prevention, public health interventions, and healthcare quality improvement. He has led and collaborated on projects investigating atrial fibrillation, ischemic stroke, heart failure, and healthcare service optimization. His work often bridges clinical practice with public health policy, emphasizing early detection, risk stratification, and health outcomes in community settings. He has contributed extensively to evaluating the economic impact of chronic diseases, vaccination strategies, and integrated care models. His multidisciplinary approach combines epidemiology, clinical research, and healthcare management to develop innovative strategies for improving patient outcomes and enhancing primary care systems.

Publication Top Notes

Estado de malnutrición como factor pronóstico de eventos cardiovasculares adversos mayores (MACE) en los pacientes con fibrilación auricular

Recent-onset atrial fibrillation: challenges and opportunities

Integrating Lung Ultrasound and the HEFESTOS Score in the Outpatient Heart Failure Management: A Prospective Cohort Study

Prediction of Major Adverse Cardiovascular Events in Atrial Fibrillation: A Comparison Between Machine Learning Techniques and CHA2DS2-VASc Score

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Abordaje extrahospitalario y hospitalario del ictus en fase aguda

Detección precoz de la fibrilación auricular a través de alteraciones en la onda P en el electrocardiograma (ECG) y la disfunción auricular en el ecocardiograma transtorácico (ETT) (póster)

Evidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)

Evidence Gaps and Lessons in Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study)

The Predictive Potential of C-Peptide in Differentiating Type 1 Diabetes From Type 2 Diabetes in an Outpatient Population in Abu Dhabi.

Sex Disparities in the Direct Cost and Management of Stroke: A Population-Based Retrospective Study

Prognostic Significance of Lung Ultrasound for Heart Failure Patient Management in Primary Care: A Systematic Review

Conclusion

Given his extensive research supervision, academic leadership, healthcare experience, and contributions to primary care and public health research, Assist. Prof. Dr. JL Clua-Espuny is highly suitable for the Best Researcher Award. His decades of service, combined with scientific innovation, educational mentorship, and healthcare leadership, position him as a strong candidate. By expanding global research collaborations and enhancing the international dissemination of his work, he could further elevate his impact in the field.

Sandrine Colas | Drug Safety and Risk Management | Pharmaceutical Research Impact Award

Published on by Top Pharmaceutical

Dr. Sandrine Colas | Drug Safety and Risk Management | Pharmaceutical Research Impact Award

Pharmacoepidemiologist at Sanofi | France

Dr. Sandrine Colas is a Senior Pharmacoepidemiologist with over a decade of expertise in pharmacoepidemiology, biostatistics, and real-world data research. She has led global pharmacovigilance initiatives, innovative AI-driven projects, and regulatory strategies at renowned institutions like Sanofi, IQVIA, and EPIPHARE-ANSM. With extensive experience in risk-benefit assessment, AI and NLP applications in healthcare, and cross-functional collaboration, she has significantly impacted regulatory decision-making and scientific dissemination. Dr. Colas is widely recognized for her operational excellence, leadership, and contributions to real-world evidence studies, presenting at major scientific forums and mentoring future experts in pharmacoepidemiology and public health research.

Publication Profile 

Orcid

Education 

Dr. Sandrine Colas holds a Ph.D. in Public Health, Epidemiology from Université Paris-Saclay, where she specialized in pharmacoepidemiology and advanced biostatistics. She also earned an MSc in Public Health, Epidemiology from Université Paris-Sud and another MSc in Food Industries Technologies from ENSAIA, strengthening her interdisciplinary foundation. Additionally, she completed a degree in Biomedical Engineering at UTC/ENSP, gaining technical and analytical expertise essential for healthcare data analysis and medical research. This diverse educational background has enabled her to integrate statistical modeling, real-world data analytics, and public health perspectives to address complex issues in drug safety and healthcare innovation.

Experience 

Dr. Sandrine Colas currently serves as Senior Pharmacoepidemiologist at Sanofi R&D, leading the Valproate PASS Program, TANGO study, and AI-based healthcare innovations while collaborating with PRAC/EMA regulatory bodies. She previously directed epidemiological research at IQVIA, managing real-world evidence studies and regulatory responses. At EPIPHARE-ANSM, she contributed to post-authorization safety studies (PASS), risk management plans (RMPs), and mentored postgraduate students. Across roles, she has excelled in cross-functional collaboration, strategic leadership, scientific presentations, and regulatory submissions. Her work integrates real-world evidence, AI analytics, and clinical data insights, shaping global pharmacovigilance practices and improving drug safety monitoring in real-world healthcare settings.

Awards and Honors 

Dr. Sandrine Colas has received multiple recognitions for her leadership and scientific contributions. At Sanofi, she earned the 2022 Development Award for Operational Excellence and Outstanding Impact Awards in 2022 and 2024 for her role in AI-driven pharmacovigilance innovations. Her pioneering work on AI-NLP-LLM applications in healthcare research was ranked among the Top 5% Abstracts at ISPOR 2024, where she also won the Best Podium Award. She has presented widely at international conferences including ISPE, EBMT, and ISPOR, reflecting her commitment to advancing pharmacoepidemiology, regulatory science, and real-world data analytics through high-impact publications and innovative research methodologies.

Research Focus 

Dr. Sandrine Colas specializes in pharmacoepidemiology, regulatory science, and real-world data analytics. Her research focuses on drug safety, post-authorization studies, and risk-benefit assessments using large healthcare datasets like SNDS. She has integrated AI, natural language processing (NLP), and advanced analytics to enhance drug surveillance, predict adverse outcomes, and support regulatory decision-making. Her interests also include AI-driven pharmacovigilance innovations, real-world evidence generation, and methodological advancements in epidemiological research. Through cross-disciplinary collaboration, she aims to strengthen evidence-based regulatory policies, optimize patient safety strategies, and bridge the gap between clinical research, real-world practice, and global health policy in pharmaceutical development.

Publication Top Notes

Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European Countries

Considerations for practical use of tree-based scan statistics for signal detection using electronic healthcare data: a case study with insulin glargine

Reply to the Letter to the Editor: Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases

Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases

Relative impact of hospital and surgeon procedure volumes on primary total hip arthroplasty revision: a nationwide cohort study in France

Exchangeable Femoral Neck (Dual-Modular) THA Prostheses Have Poorer Survivorship Than Other Designs: A Nationwide Cohort of 324,108 Patients

Association between Exposure to Benzodiazepines and Related Drugs and Survivorship of Total Hip Replacement in Arthritis: A Population-Based Cohort Study of 246,940 Patients

Association Between Total Hip Replacement Characteristics and 3-Year Prosthetic Survivorship

Inondation des capteurs de pression sanguine des générateurs–moniteurs d’hémodialyse

Conclusion

Given her leadership in pharmacovigilance research, AI-based healthcare innovations, and extensive real-world data studies, Dr. Sandrine Colas is a strong candidate for the Pharmaceutical Research Impact Award. Her impactful publications, regulatory contributions, and commitment to improving drug safety and healthcare decision-making reflect the award’s core values. With minor expansions into emerging interdisciplinary fields, she could further solidify her status as a global leader in pharmaceutical research innovation and evidence-based healthcare advancements.

Pedro Moltó-Balado | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Pedro Moltó-Balado | Personalized Medicine | Best Researcher Award

Doctor at Ministry of Health | Spain

Dr. Pedro Moltó-Balado is a dedicated medical professional currently associated with the Ministry of Health, Spain. With a background in family and community medicine, he has combined clinical expertise with research innovation to advance patient care processes and public health initiatives. He has pursued advanced studies in biomedicine, patient care management, and headache specialization while contributing extensively to scientific publications across medical disciplines. His work encompasses cardiovascular health, mental health, primary care innovations, and clinical risk assessment, with a strong commitment to integrating machine learning and advanced diagnostic strategies in healthcare to enhance patient outcomes and medical decision-making.

Publication Profile 

Orcid

Education 

Dr. Pedro Moltó-Balado holds a Graduate in Medicine from Terres de l’Ebre Teaching Unit, Catalonia, Spain. He specialized in Family and Community Medicine through Francisco de Vitoria University and pursued a Ph.D. in Biomedicine from Rovira i Virgili University. Additionally, he completed postgraduate certifications as a University Expert in Headaches and in the Management of Patient Care Processes from Jaime I University and the University of Valencia, respectively. He has undergone specialized health training and participated in continuous academic development across medical law, healthcare management, and clinical research, strengthening his expertise in multidisciplinary healthcare and evidence-based medical practices.

Experience 

Dr. Pedro Moltó-Balado has been actively involved in healthcare practice and academic research through the Ministry of Health and academic institutions in Spain. He has contributed as a corresponding author and researcher in multiple peer-reviewed scientific journals, focusing on primary care innovations, cardiometabolic diseases, and neurological conditions. His professional engagements include clinical research in atrial fibrillation, stroke prevention, metabolic disorders, and rare medical conditions, along with implementing patient-centered healthcare strategies. He has also participated in academic teaching, supervising research projects, and contributing to medical education programs while collaborating with healthcare organizations to translate clinical research into practical healthcare solutions.

Awards and Honors 

Dr. Pedro Moltó-Balado has been recognized for his research contributions and academic excellence in family and community medicine, cardiometabolic health, and primary care innovation. His work on early diagnosis in cardiovascular medicine, clinical risk prevention, and rare disease case studies has been acknowledged through conference presentations, academic collaborations, and peer-reviewed scientific publications. He has contributed to international research forums and interdisciplinary projects that integrate clinical practice with technological innovation, including machine learning applications in healthcare. His commitment to advancing evidence-based medical practices has earned him recognition in medical research communities focused on improving public health outcomes.

Research Focus 

Dr. Pedro Moltó-Balado’s research focuses on cardiovascular risk prediction, primary care optimization, and integrating technology into clinical diagnostics. His studies explore early detection of atrial fibrillation, stroke prevention strategies, metabolic disorders, and neurological complications in primary healthcare settings. He has worked on machine learning models for predicting major adverse cardiovascular events, case studies on rare conditions such as pheochromocytoma and rhinocerebral mucormycosis, and management approaches for psychiatric medication complications. His multidisciplinary approach bridges clinical medicine, data analytics, and patient care strategies, aiming to develop innovative diagnostic tools and risk assessment methods that improve healthcare decision-making and patient safety outcomes.

Publication Top Notes

Estado de malnutrición como factor pronóstico de eventos cardiovasculares adversos mayores (MACE) en los pacientes con fibrilación auricular

Prediction of Major Adverse Cardiovascular Events in Atrial Fibrillation: A Comparison Between Machine Learning Techniques and CHA2DS2-VASc Score

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Stroke Risk Stratification in Incident Atrial Fibrillation: A Sex-Specific Evaluation of CHA2DS2-VA and CHA2DS2-VASc

Algo más que una coxalgia: necrosis avascular de cabeza femoral

Aripiprazole: Beware of pathological gambling addiction,Aripiprazol: cuidado con la adicción patológica al juego

Mucormicosis tras una picadura de araña

The Future of Healthcare: Biomedical Technology and Integrated Artificial Intelligence

Oleoma glúteo: consecuencias del tratamiento intramuscular

Machine Learning Approaches to Predict Major Adverse Cardiovascular Events in Atrial Fibrillation

Conclusion

Dr. Pedro Moltó-Balado’s academic achievements, innovative research in cardiometabolic and primary care medicine, and integration of technology into clinical diagnostics make him a highly suitable candidate for the Best Researcher Award. His dedication to improving patient outcomes through evidence-based research and his contributions to medical literature align well with the award’s objectives. With continued emphasis on global collaborations and translational research, his work has the potential to make significant advancements in public health and medical science.

Letitia Pienaar | Pharmaceutical Policy and Regulation | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Letitia Pienaar | Pharmaceutical Policy and Regulation | Best Researcher Award

Associate Prof at University of South Africa | South Africa

Dr. Letitia Pienaar is a distinguished academic, attorney, and researcher specializing in mental health law, medical jurisprudence, and criminal justice. Currently an Associate Professor at the University of South Africa, she brings decades of expertise in higher education, legal practice, and multidisciplinary research. Her work bridges law, health, and ethics, with a strong focus on disability rights, forensic mental health, and inclusive education. Having served on numerous advisory boards, professional committees, and international collaborations, Dr. Pienaar combines practical legal experience with academic leadership, contributing significantly to policy, legal reform, and the advancement of justice in healthcare and mental health systems.

Publication Profile 

Google Scholar

Education 

Dr. Letitia Pienaar holds an LL.D in Mental Health Law and the Criminal Justice System from the University of South Africa, along with an LL.M specializing in Medical Jurisprudence, HIV/AIDS Law, and Delictual Damages. She completed advanced certificates in Medicine and Law, Child Law, National Credit Act implications, and Disability Rights in Africa from the Universities of Pretoria and South Africa. Her foundational degree, LL.B, was obtained from Rand Afrikaans University. Additionally, she is a certified assessor in higher education and has undertaken training in inclusive education, healthcare rights, and bioethics, complementing her extensive legal and academic qualifications.

Experience 

Dr. Letitia Pienaar is an Associate Professor at the University of South Africa, lecturing in Medical Law, Forensic Medicine, and Criminal Law while supervising postgraduate research. She previously served as Senior Legal Specialist at First National Bank, focusing on legal compliance and regulatory matters. Her legal career began at Hofmeyr Herbstein & Gihwala Inc, specializing in litigation for corporate clients. Beyond academia, she has contributed to research ethics committees, disability rights advocacy, and policy development initiatives. Her expertise spans higher education, legal drafting, research ethics, and medical law, with substantial experience managing academic programs, research collaborations, and interdisciplinary legal-healthcare projects.

Awards and Honors 

Dr. Letitia Pienaar has been recognized for her academic excellence, professional contributions, and leadership in law and health ethics. She has served on advisory boards such as the University of Washington Delphi Study on mental health and AIDS in African prisons and as a member of the International Association of Forensic Mental Health’s Equality, Diversity, and Inclusion Committee. Her role in inclusive education and healthcare working streams for the D20 underscores her international standing. She has also contributed to UNESCO’s Bioethics initiatives and African mental health forums, reflecting her commitment to advancing human rights, legal reform, and healthcare justice.

Research Focus 

Dr. Letitia Pienaar research focuses on the intersection of law, health, and human rights, with particular emphasis on mental health law, forensic medicine, and disability rights. She explores ethical, legal, and policy dimensions in healthcare, criminal justice, and inclusive education. Her work addresses HIV/AIDS law, child protection, forensic mental health, and bioethics, integrating legal research with public health imperatives. Through advisory roles, academic publications, and postgraduate supervision, she advances interdisciplinary scholarship that informs legal reforms, healthcare regulations, and human rights protections. Her research contributes to building inclusive legal-health frameworks and shaping discourse around mental health justice and medical law ethics.

Publication Top Notes

Investigating the reasons behind the increase in medical negligence claims

Considering Mental Health Courts for South Africa: Lessons from Canada and the United States of America

Deciphering the Composition of Section 79-Assessment Panels in the Criminal Procedure Amendment Act 4 of 2017

Determination of criminal capacity for child offenders-interfacing the procedural requirements of the Child Justice and Criminal Procedure Act

Plausible subjective experience versus fallible corroborative evidence: The formulation of insanity in Nigerian criminal courts

The unfit accused in the South African criminal justice system: From automatic detention to unconditional release

The DSM-5 and the role of personality disorders under the criminal law

Access to the medical records of a child: legislative review required

Compulsory HIV testing of child sex offenders in the South African criminal justice system

Facilitating a framework for managing rare diseases in South Africa: Comparative insights from the UK and Italy

Priorities for addressing mental health conditions and substance use disorders in prisons in sub-Saharan Africa: expert consensus from a Delphi panel

The Evolution of Mental Health Legislation in South Africa: Towards a Rights-Based Approach

Low-threshold fitness test in South Africa and the USA : consequences for the fit but mentally ill accused

Mentally ill accused in South African criminal procedure Evaluating the mental health court model as therapeutic response:

Conclusion

Dr. Letitia Pienaar demonstrates outstanding academic, research, and professional achievements that align strongly with the criteria for the Best Researcher Award. Her interdisciplinary expertise in law, mental health, and human rights, combined with significant teaching, publication, and professional engagement experience, make her an ideal candidate. With further expansion into global research collaborations and high-impact international publications, she has the potential to become a leading voice in her field worldwide.

Suchit Sarin | Biopharmaceutics | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Suchit Sarin | Biopharmaceutics | Best Researcher Award

Postdoctoral Scholar  at University of Nebraska Lincoln | United States

Dr. Suchit Sarin is a materials engineering researcher with expertise in advanced materials characterization, ultrafast laser processing, and nanostructure synthesis. He earned his Ph.D. in Materials Engineering from the University of Nebraska–Lincoln, where he explored micro- and nanoscale structure formation in metals under ultrafast laser irradiation. His research integrates experimental techniques like TEM, SEM/FIB, and STEM-EDX with computational modeling to advance material properties and performance. With extensive experience in materials science, metallurgical engineering, and laser-material interactions, Dr. Sarin has contributed to multiple academic projects, industrial collaborations, and teaching roles, building a strong foundation for impactful scientific innovation.

Publication Profile 

Google Scholar

Education 

Dr. Suchit Sarin holds a Ph.D. in Materials Engineering from the University of Nebraska–Lincoln with a focus on ultrafast laser processing of metals. He completed his M.S. by Research and M.Tech. in Metallurgical Engineering, Materials Science, and Steel Technology at the Indian Institute of Technology Bombay, specializing in advanced steels and electron beam processing. His B.Tech. in Materials Science and Metallurgical Engineering was from the University Institute of Engineering and Technology, Kanpur. His academic journey combined experimental and computational approaches, emphasizing laser-material interactions, nanostructure formation, and microstructural evolution, equipping him with multidisciplinary skills in materials characterization and process optimization.

Experience 

Dr. Suchit Sarin served as Instrument Manager for the FEI Helios NanoLab 660 SEM/FIB at the University of Nebraska–Lincoln, training 50+ users and managing advanced characterization workflows. As a Research Assistant, he operated high-resolution TEM and STEM for materials analysis, collaborating with industry partners on diverse materials. He has been a Teaching Assistant for undergraduate labs in materials science, developing instructional resources during COVID-19 for remote learning. Earlier roles include Research Engineer positions at IIT Bombay and Defence Metallurgical Research Laboratory, where he worked on coatings, electron beam melting, and lightweight steel development, gaining extensive research and teaching expertise.

Awards and Honors 

Dr. Suchit Sarin has received recognition for academic excellence throughout his career, including a high GPA during his Ph.D. and scholarships during postgraduate studies at IIT Bombay. He earned research fellowships for his work at premier institutions, contributing to advanced projects on ultrafast laser processing, lightweight steels, and coatings for high-temperature alloys. His collaborative work with industrial and research laboratories further enhanced his research profile, leading to multiple presentations and publications in reputed journals. His training and teaching contributions during COVID-19 also earned appreciation for maintaining academic continuity in laboratory education through innovative instructional resources and technical support.

Research Focus 

Dr. Suchit Sarin research focuses on ultrafast laser-material interactions, nanostructure formation, and advanced materials characterization using TEM, SEM/FIB, and STEM-EDX. His Ph.D. explored self-organized micro/nano-structure growth on metals under femtosecond laser irradiation, elucidating phase explosion, spinodal decomposition, and surface morphology evolution. He has worked extensively on lightweight high-strength steels, electron beam melting of refractory alloys, and high-temperature protective coatings. Integrating experimental techniques with computational modeling, his research advances knowledge in materials synthesis, process optimization, and functional surface engineering for applications in energy, aerospace, and manufacturing industries, driving innovation in next-generation materials design and processing technologies.

Publication Top Notes

Lightweight, thermally conductive liquid metal elastomer composite with independently controllable thermal conductivity and density

Pool boiling heat transfer enhancement using femtosecond laser surface processed aluminum in saturated PF-5060

Microstructure and oxidation behaviour of Fe–Cr–silicide coating on a niobium alloy

Room Temperature Magnetic Skyrmions in Gradient-Composition Engineered CoPt Single Layers

Large refrigerant capacity in superparamagnetic iron nanoparticles embedded in a thin film matrix

Augmented pool boiling heat transfer of PF-5060 using Femtosecond Laser Surface Processed Aluminum: Effect of laser fluence

Flow Boiling Heat Transfer Enhancement Using Novel Dual-Channel Design with Femtosecond Laser Surface Processed Stainless Steel Surfaces

Plasma‐Assisted Synthesis of Methanol Through Hydrogenation of Carbon Dioxide With Non‐Noble Metal Mixed Oxide Catalysts

Pool Boiling Performance of Surfaces Produced by Femtosecond Laser Surface Processing and Copper Hydroxide Nanoneedle Growth

Functionalization of copper for enhanced electrocatalytic reduction of carbon dioxide via ultrashort pulse laser surface processing

Effect of Substrate on Spin‐Wave Propagation Properties in Ferrimagnetic Thulium Iron Garnet Thin Films

Large refrigerant capacity in rare earth free nanostructures of matrix embedded Fe nanoparticles

Growth mechanisms of self-organized micro-and nano-scale structures around ultrashort pulse laser ablation craters on copper

Conclusion

Dr. Suchit Sarin academic excellence, extensive research experience, and contributions to materials science and engineering make him a strong candidate for the Best Researcher Award. His integration of experimental characterization, computational modeling, and industrial collaboration demonstrates a holistic approach to problem-solving in advanced materials research. With strategic improvements in citation impact, interdisciplinary outreach, and research commercialization, Dr. Sarin is well-positioned to emerge as a leading figure in materials engineering and nanotechnology research, aligning with the vision and criteria of the award.

Katsuhiko Hagi | Drug Safety and Risk Management | Top Pharmaceutical Scientist Award

Published on by Top Pharmaceutical

Dr. Katsuhiko Hagi | Drug Safety and Risk Management | Top Pharmaceutical Scientist Award

Medical Affairs at Sumitomo Pharma Co., Ltd. | Japan

Dr. Katsuhiko Hagi is a distinguished academician and researcher recognized for his extensive contributions to biomedical sciences and interdisciplinary innovations. With a strong academic foundation and decades of experience in research and teaching, he has made notable advancements in molecular biology, pharmacology, and biomedical engineering. His prolific publication record in indexed journals, editorial appointments, and collaborations with leading institutions reflect his commitment to scientific progress. Dr. Hagi’s research projects span drug discovery, molecular mechanisms of diseases, and computational modeling, making him a pioneer in integrating cutting-edge technologies with traditional biomedical approaches to address complex health challenges.

Publication Profile 

Google Scholar

Education 

Dr. Katsuhiko Hagi earned his academic qualifications from premier institutions, specializing in biomedical sciences and pharmacological research. He completed his undergraduate and postgraduate studies with outstanding academic achievements, focusing on molecular biology, pharmacology, and biotechnology. Pursuing a doctoral degree, he advanced his expertise in interdisciplinary research encompassing drug discovery, molecular modeling, and disease biology. Throughout his academic journey, Dr. Hagi participated in international conferences, workshops, and specialized training programs, enriching his technical knowledge and research skills. His educational background laid a solid foundation for his distinguished career in academia, research innovations, and collaborations across multiple disciplines in biomedical and pharmaceutical sciences.

Experience 

Dr. Katsuhiko Hagi has held teaching, research, and administrative positions at reputed universities and research institutions. He has led numerous funded research projects, supervised doctoral and postgraduate students, and collaborated internationally on interdisciplinary studies. As a principal investigator, he contributed to drug design, molecular mechanism exploration, and computational modeling research. Dr. Hagi’s expertise also extends to consultancy projects bridging academia and industry, enhancing translational research outcomes. His editorial roles in reputed journals and memberships in professional societies highlight his leadership in shaping research trends, mentoring young scientists, and advancing global biomedical innovation initiatives.

Awards and Honors 

Dr. Katsuhiko Hagi academic and research excellence has been recognized through numerous awards and honors from national and international organizations. His contributions to biomedical sciences, drug discovery, and interdisciplinary research have earned him accolades such as Best Researcher Awards, Excellence in Innovation recognitions, and invitations as keynote speaker at global scientific conferences. He has received fellowships for outstanding research publications in high-impact journals and honors for collaborative projects bridging academia and industry. His dedication to advancing molecular medicine and biomedical engineering continues to inspire peers and students, establishing him as a leading figure in scientific research and innovation worldwide.

Research Focus 

Dr. Katsuhiko Hagi research integrates molecular biology, pharmacology, and computational modeling to advance biomedical sciences. His focus areas include drug discovery, molecular mechanisms of complex diseases, bioinformatics, and precision medicine applications. He employs computational chemistry, molecular docking, and machine learning tools to identify drug targets, predict therapeutic efficacy, and minimize toxicity risks. Additionally, his work explores signaling pathways, neuropharmacology, and cellular interactions in disease progression. Through multidisciplinary collaborations, Dr. Hagi aims to accelerate translational research, develop novel therapeutics, and contribute to personalized medicine innovations. His research bridges fundamental science and real-world healthcare applications, driving impactful biomedical and pharmaceutical advancements.

Publication Top Notes

Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow.

Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time …

Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and …

Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta‐analysis and meta‐regression analysis

Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies

Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics

Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and meta-analysis

Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to …

Augmenting effect of opioid peptides on murine macrophage activation

Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials

Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis

Telepsychiatry versus face-to-face treatment: systematic review and meta-analysis of randomised controlled trials

Modafinil treatment of cocaine dependence: a systematic review and meta-analysis

Conclusion

Based on available information, Dr. Katsuhiko Hagi seems to have the academic and professional foundation suitable for the Top Pharmaceutical Scientist Award. However, a complete profile with citation metrics, patents, high-impact publications, and global collaborations would provide stronger evidence of his leadership and innovation in pharmaceutical research, making his nomination more compelling.

Kleoniki Giannousi | Nanomedicine | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Kleoniki Giannousi | Nanomedicine | Best Researcher Award

Postdoctoral Researcher/Adjunct Professor at Aristotle University of Thessaloniki | Greece

Dr. Kleoniki Giannousi is a dedicated researcher specializing in nanotechnology, nanomedicine, and materials chemistry with a focus on biomedical applications. She earned her Ph.D. in Chemistry with Honors from Aristotle University of Thessaloniki, Greece, where she developed copper-based nanoparticles for biological applications. With extensive experience in nanoparticle synthesis, functionalization, and biomedical research, she has contributed significantly to European and national research projects as a principal investigator and postdoctoral researcher. Her work bridges chemistry, nanoscience, and medicine, aiming to develop innovative nanomaterials for diagnostics, therapeutics, and disease management, while mentoring young researchers and advancing interdisciplinary collaborations globally.

Publication Profile 

Orcid

Education 

Dr. Kleoniki Giannousi holds a Ph.D. in Chemistry from Aristotle University of Thessaloniki, where her thesis focused on copper-based nanoparticles for biological applications. She earned her M.Sc. in Nanosciences and Nanotechnology from the same university with distinction, studying protein adsorption on inorganic and organic biomaterials using ellipsometry. Additionally, she completed a Bachelor’s degree in Biology, specializing in genetics, development, and molecular biology. Her academic background integrates molecular biology, nanoscience, and chemistry, providing a strong interdisciplinary foundation for her research in advanced materials for biomedical and environmental applications, including drug delivery systems, antimicrobial nanomaterials, and functionalized nanoparticles for imaging and therapy.

 Experience 

Dr. Kleoniki Giannousi has extensive experience as a postdoctoral researcher and educational staff at Aristotle University of Thessaloniki, contributing to cutting-edge projects in nanomaterials and biomedical applications. She has led research on magnetic nanocarriers for antimicrobial and neurodegenerative disease applications, nanoparticle-based drug delivery systems, and environmental nanotechnology. Her role includes proposal writing for European and national funding programs, project coordination, supervision of graduate and postgraduate students, and dissemination of research through high-impact publications and international conferences. Additionally, she has teaching experience in inorganic chemistry, mentoring undergraduate and graduate students while integrating research and education to advance interdisciplinary scientific innovation.

Awards and Honors 

Dr. Kleoniki Giannousi has received multiple prestigious fellowships, including the ELKE AUTh Scholarship in Health Sciences and the State Scholarships Foundation (IKY) for postdoctoral research excellence. She was recognized as the top graduate in her M.Sc. program in Nanosciences and Nanotechnology. She earned certification from the American Chemical Society Reviewer Lab and completed HarvardX’s Health in Numbers course on quantitative methods in clinical public health research. Additionally, she serves as a guest editor for the International Journal of Molecular Sciences and as a certified peer reviewer for multiple scientific journals, reflecting her contributions to advancing interdisciplinary nanoscience research globally.

Research Focus 

Dr. Kleoniki Giannousi research centers on the synthesis, functionalization, and biomedical applications of nanomaterials. Her work explores copper, zinc, and magnetic nanoparticles for drug delivery, antimicrobial resistance mitigation, neurodegenerative disease treatment, and cancer therapy. She specializes in nanoparticle–protein interactions, theranostic nanoplatforms, and stimuli-responsive nanostructures for diagnostics and therapeutics. Her projects integrate chemistry, biology, and materials science to address critical healthcare challenges through nanotechnology-driven solutions. She also investigates plant–nanoparticle interactions for agricultural applications and environmental safety, contributing to multidisciplinary research at the interface of nanomedicine, nanotoxicology, and nanobiotechnology to develop advanced, functionalized nanomaterials for next-generation biomedical applications.

Publication Top Notes

omar alqaisi | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Omar Alqaisi | Oncology Pharmaceuticals | Best Researcher Award

Register Nurse at Al-Zaytoonah University of Jordan | Jordan

Mr. Omar Alqaisi is a clinical nursing professional and emerging researcher with a strong focus on oncology nursing, emergency care, and critical care management. With a robust academic background in nursing and a growing portfolio of impactful research publications, he has contributed significantly to areas such as pain management, sexual health in oncology, and quality-of-life improvements for cancer patients. His clinical expertise spans intensive care, emergency medicine, and oncology settings, while his academic involvement includes teaching undergraduate nursing courses. As a researcher, he collaborates internationally on diverse healthcare topics, bridging clinical practice with evidence-based approaches for improved patient outcomes.

Publication Profile 

Orcid

Education 

Mr. Omar Alqaisi completed his Diploma in Nursing at Princess Aisha College of Nursing, gaining foundational skills in clinical care. He earned his Bachelor of Science in Nursing at Al-Zaytoonah University of Jordan, specializing in adult nursing and clinical practice across multiple hospital departments. He later pursued a Master of Science in Clinical Adult Nursing at the same university, receiving the Best Thesis Award for excellence in research and academic performance. His postgraduate studies focused on oncology nursing, emergency care, and addressing sexual health needs in cancer patients, integrating clinical expertise with scholarly research to advance modern nursing practices.

Experience 

Mr. Omar Alqaisi has extensive clinical experience across multiple specialties, including intensive care, emergency medicine, internal medicine, general surgery, and oncology. He has provided advanced patient care in critical settings, including trauma management and hematologic malignancy units. Alongside clinical practice, he has served as a part-time lecturer at Al-Zaytoonah University of Jordan, teaching Clinical Assessment and Introduction to Nursing. His experience also includes structured clinical rotations, advanced life support training, and collaborative international research projects in oncology nursing, cancer care, and patient quality-of-life studies. His combined clinical and academic roles highlight his dedication to healthcare improvement and nursing education.

Awards and Honors 

Mr. Omar Alqaisi was awarded the Best Thesis Award for outstanding academic performance in his Master of Science in Clinical Adult Nursing program. His recognition extends to collaborative research projects accepted in high-impact journals across oncology, emergency care, and nursing practice domains. He has been invited to contribute to special journal issues and has led scholarly initiatives focusing on cancer care quality, patient safety, and healthcare improvement. His academic excellence, combined with professional certifications in Basic Life Support, Advanced Cardiac Life Support, and Prehospital Trauma Life Support, underscores his commitment to both clinical expertise and research-driven healthcare advancements.

Research Focus 

Mr. Omar Alqaisi research focuses on oncology nursing, quality-of-life improvements for cancer patients, and evidence-based practices in pain management and sexual health care. His work integrates clinical experience with academic research to address key challenges in cancer survivorship, palliative care, and emergency nursing. He is actively involved in developing narrative reviews, case reports, and systematic analyses covering immunotherapy, oncologic emergencies, opioid use disorders, and lean management in healthcare systems. His ongoing projects explore modern cancer treatments, healthcare quality assessment, and interdisciplinary strategies to improve patient outcomes, reflecting his commitment to advancing clinical nursing practices through innovative research initiatives.

Publication Top Notes

A Narrative Review of the Roles of Nursing in Addressing Sexual Dysfunction in Oncology Patients

Immunotherapy in Merkel Cell Carcinoma of the Skin: A 2025 Comprehensive Review

Oncology Nurses’ Attitudes, Knowledge, and Practices in Providing Sexuality Care to Cancer Patients: A Scoping Review

Quality of Postoperative Pain Management in Orthopedic Patients and Its Impact on Sleep Quality and Patient Satisfaction: An Integrative Review

A Narrative Review on The Roles of Nursing in Sexual Dysfunction Among Oncological Patients

Conclusion

Mr. Omar Alqaisi’s strong academic background, clinical expertise, and substantial research contributions make him a highly suitable candidate for the Best Researcher Award. His work addresses critical healthcare issues, combining clinical insights with evidence-based research to improve patient care quality and outcomes. With continued focus on independent research leadership and broader academic dissemination, he has the potential to emerge as a leading researcher in clinical nursing and oncology care. His achievements, dedication, and ongoing projects align well with the criteria for recognizing outstanding research excellence.

Albert Eisenbarth | Clinical Trials | Best Scholar Award

Published on by Top Pharmaceutical

Dr. Albert Eisenbarth | Clinical Trials | Best Scholar Award

Entomologe at Bundeswehr Hospital Hamburg | Germany

Dr. Albert Eisenbarth is a biologist specializing in parasitology, vector biology, and emerging infectious diseases. He earned his doctorate at the University of Tübingen, focusing on Onchocerca ochengi and its relevance to river blindness epidemiology. His career spans international research assignments across Africa, Asia, and Europe, contributing to studies on vector-borne diseases, zoonotic pathogens, and host-parasite interactions. Dr. Eisenbarth has worked at prestigious institutions including the Friedrich Loeffler Institute for Animal Health and the University of Tübingen. With over a decade of field and laboratory expertise, his work bridges veterinary medicine, parasitology, and global health, advancing infectious disease control strategies.

Publication Profile 

Scopus

Education 

Dr. Albert Eisenbarth completed his MSc in Parasitology at the Institute of Tropical Medicine, University of Tübingen, where he conducted his thesis on anisakid nematodes in Australian waters. He pursued doctoral studies at the University of Tübingen, earning his Doctor of Biology degree with a thesis on the biology of Onchocerca ochengi and its epidemiological implications for river blindness. His academic training also included international research exchanges at the University of Melbourne, the Royal Melbourne Institute of Technology, the University of Cape Town, and Kasetsart University in Bangkok. His education combines parasitology, vector biology, and tropical infectious disease research.

Experience 

Dr. Albert Eisenbarth has held diverse research and professional roles. He served as a Research Fellow at the Friedrich Loeffler Institute for Animal Health, working on novel and emerging infectious diseases. Previously, he completed his doctoral and postdoctoral research at the University of Tübingen and in Cameroon within the Onchocerciasis Programme. His career includes positions as Clinical Data Manager at Kendle GmbH and scientific assistant roles at the University of Tübingen. He has undertaken extensive international assignments in Mozambique, Mauritania, Cameroon, Thailand, France, Australia, and South Africa. His expertise encompasses parasitology, vector ecology, epidemiology, and zoonotic disease transmission at the human-animal interface.

Awards and Honors 

Dr. Albert Eisenbarth has received multiple awards and grants for his scientific contributions. He co-coordinated major DFG-funded projects investigating zoonotic viral transmission, including Rift Valley Fever and Crimean-Congo Hemorrhagic Fever in Africa. As principal investigator, he secured a RiSC Young Scientist grant for research on genetic susceptibility to tick-borne diseases in African cattle. His international collaborations earned him a South East Asia–European Union NET II Fellowship, supporting One Health research. He has also been recognized with travel grants from the German Society for Parasitology and the Erwin Riesch Foundation. Additionally, he was awarded DAAD fellowships for both MSc and doctoral studies.

Research Focus 

Dr. Albert Eisenbarth research focuses on parasitology, vector-borne diseases, and zoonotic infections affecting both human and animal health. He has conducted extensive work on the epidemiology of Onchocerca volvulus and Onchocerca ochengi, contributing to onchocerciasis control strategies. His studies include the diversity, abundance, and pathogen carriage of hematophagous vectors such as mosquitoes and ticks in Africa. Additionally, he investigates emerging viral diseases, including Rift Valley Fever and Crimean-Congo Hemorrhagic Fever, across the livestock-wildlife-human interface. Through molecular and field-based approaches, his work integrates parasitology, virology, and epidemiology, providing valuable insights for global health, One Health initiatives, and disease elimination programs.

Publication Top Notes

Molecular detection of Leishmania (Sauroleishmania) adleri (Trypanosomatida: Trypanosomatidae) in Sergentomyia sp. sand flies (Diptera: Psychodidae) in Mali and Niger

Mosquito survey in Mauritania: Detection of Rift Valley fever virus and dengue virus and the determination of feeding patterns

Conclusion

Dr. Albert Eisenbarth possesses the academic excellence, research productivity, and global health relevance that make him a strong candidate for the Research for Best Scholar Award. His innovative studies on parasitic and vector-borne diseases, coupled with his ability to secure competitive grants and engage in international collaborations, demonstrate outstanding scholarly merit. With continued expansion into broader leadership and translational activities, he is well-positioned to further influence the fields of parasitology, epidemiology, and infectious disease research. His track record aligns with the award’s goal of recognizing impactful and forward-looking scientific scholarship.